Tampa Bay's Morning Blend


BioMarker Status and Lung Cancer Treatment

Posted at 9:49 AM, Sep 08, 2021
and last updated 2021-09-10 11:42:04-04

For roughly 1 in 8 U.S. Patients with non-small cell lung Cancer, knowing their biomarker status could unlock the door to a newly approved treatment.

Non-small cell lung cancer (NSCLC) accounts for approximately 84% of the 2.2 million new lung cancer diagnoses each year worldwide, including approximately 236,000 new cases in the U.S. We speak with a Physician about the critical role Biomarker Testing can play in detecting a form of lung cancer caused by a genetic mutation.

LUMAKRAS™ is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Paid for by Amgen

Tampa Bay's Morning Blend

9:57 PM, Oct 16, 2018

Tampa Bay’s Morning Blend is an original, local lifestyle show focused on providing our audience with informative, useful and entertaining content. It features a variety of community organizations, businesses and happenings in the Bay area. It is a marketing-friendly program dedicated to offering businesses the opportunity to showcase their company/products, reach potential customers and gain results.

Grow Your Business With Us!
For Sponsor Information: